Project Grant R15AR085909
Award Date 9/1/25
Completion Date 7/31/28
Dollars Obligated $551K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stillwater, OK 74078, USA
Similar Awards
- This federal Project Grant award of $646,506 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting the development of dual-action nanoparticle-loaded microparticles for the treatment of osteoarthritis (OA). The research aims to create innovative nanoparticle-based therapeutics that can stimulate the anabolic activity of chondroprogenitors to enhance cartilage...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $312,323 Project Grant to Knoubis Bio Inc. under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports the development of a novel bispecific biologic therapy for rheumatoid arthritis (RA) that targets the transmembrane tyrosine phosphatase PTPRS. The key activities under this Phase I project include conducting pharmacokinetic studies in mice...
- This $297,327 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports Navega Therapeutics, Inc. in reformulating their NT-Z001 gene therapy to treat rheumatoid arthritis. The goal is to enable localized joint injections instead of the more invasive intrathecal delivery route. NT-Z001 targets the NAV1.7 sodium channel, a key mediator of pain, with the...
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant of $413,655 on August 1, 2025 to Arizona State University (ASU) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop biomaterials with temporal control of proteins, such as Bone Morphogenetic Proteins (BMPs), to enhance bone repair. The research aims to mimic natural extracellular matrix interactions and synergies...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is providing $1,958,125.00 to the University of Oregon to develop an innovative nanoparticle drug delivery system to improve tendon regeneration following acute injuries. The researchers aim to leverage a novel peptide that specifically targets and binds to inflammation markers in healing...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to investigate the molecular mechanisms of TAK1 regulation in rheumatoid arthritis (RA). The $1,407,925 award to Washington State University, effective August 12, 2025 through July 31, 2028, will focus on understanding how TAK1, a key signaling mediator, regulates the...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- This $527,760 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research on the role of endogenous retroviruses in autoimmune diseases like rheumatoid arthritis (RA). The award to the University of California, San Francisco will support a study to identify the specific antigens and mechanisms by which self-reactive T cells evade tolerance and...